Free Trial
NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Sunshine Biopharma logo
$1.60 +0.04 (+2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$1.60 0.00 (0.00%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Key Stats

Today's Range
$1.56
$1.61
50-Day Range
$1.23
$1.70
52-Week Range
$1.17
$7.18
Volume
74,803 shs
Average Volume
599,689 shs
Market Capitalization
$7.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Sunshine Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

SBFM MarketRank™: 

Sunshine Biopharma scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sunshine Biopharma has received no research coverage in the past 90 days.

  • Read more about Sunshine Biopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sunshine Biopharma has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Sunshine Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.09% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 38.34%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sunshine Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sunshine Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.09% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 38.34%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sunshine Biopharma has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Sunshine Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for SBFM on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of Sunshine Biopharma is held by insiders.

  • Percentage Held by Institutions

    41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sunshine Biopharma's insider trading history.
Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBFM Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
SBFM - Sunshine Biopharma Inc News - Morningstar
Sunshine Biopharma, Inc. (SBFM) - Yahoo Finance
Sunshine Biopharma launches Everolimus in Canada
See More Headlines

SBFM Stock Analysis - Frequently Asked Questions

Sunshine Biopharma's stock was trading at $3.00 on January 1st, 2025. Since then, SBFM stock has decreased by 46.8% and is now trading at $1.5950.

Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.44) earnings per share (EPS) for the quarter. The business had revenue of $8.90 million for the quarter. Sunshine Biopharma had a negative net margin of 13.88% and a negative trailing twelve-month return on equity of 21.25%.

Shares of Sunshine Biopharma reverse split before market open on Wednesday, April 17th 2024.The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/15/2025
Today
7/10/2025
Next Earnings (Estimated)
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SBFM
CIK
1402328
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+840.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.13 million
Pretax Margin
-14.70%

Debt

Sales & Book Value

Annual Sales
$34.87 million
Price / Cash Flow
N/A
Book Value
$9.10 per share
Price / Book
0.18

Miscellaneous

Free Float
4,551,000
Market Cap
$7.27 million
Optionable
Not Optionable
Beta
1.44
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:SBFM) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners